Sally Bridget Lawlor - 31 Aug 2026 Form 4 Insider Report for Quoin Pharmaceuticals, Ltd. (QNRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: QNRX
Reported as of: 31 Aug 2026
Net transaction value: +$49,991
SEC form: 4
Accepted by SEC: 01 Sep 2026, 21:39:14 UTC
Prior SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Sally Bridget Lawlor

Key filing fact

Sally Bridget Lawlor filed Form 4 for Quoin Pharmaceuticals, Ltd. (QNRX) on 01 Sep 2026.

Key facts

This page summarizes Sally Bridget Lawlor's Form 4 filing for Quoin Pharmaceuticals, Ltd. (QNRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Sep 2026, 21:39.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: +$49,991.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002084407 Primary reporting owner

Lawlor Sally Bridget

Relationship: Chief Financial Officer
Address: C/O QUOIN PHARMACEUTICALS LTD.,, 42127 PLEASANT FOREST COURT, ASHBURN
Signature: /s/ Sally Bridget Lawlor
Signature date: 01 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

QNRX transaction

ADSs

Purchase

Transaction value: $49,991
Shares: +10,244
Change %: +2328%
Price: $4.88
Shares after: 10,684
Date: 31 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

QNRX transaction Derivative

Ordinary Warrants (Right to Buy)

Purchase

Transaction value
Shares: +5,122
Change %
Price
Shares after: 5,122
Date: 31 Aug 2026
Ownership: Direct
Underlying class: ADS
Underlying amount: 5,122
Exercise price: $6.10
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

Footnote F2

Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.

Footnote F3

The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap.

Footnote F4

The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome.